Yorvipath (palopegteriparatide) is an FDA-approved medication for adults with chronic hypoparathyroidism — a rare condition in which the parathyroid glands do not produce enough parathyroid hormone (PTH), leading to low blood calcium. Yorvipath is the first approved PTH replacement therapy that mimics the natural continuous action of PTH.
🔬 Yorvipath at Our Clinic: Our endocrinologists manage hypoparathyroidism and prescribe Yorvipath for appropriate patients. Book a consultation at 832-968-7003.
What Is Hypoparathyroidism?
Hypoparathyroidism is a condition in which the parathyroid glands fail to produce adequate PTH. Without enough PTH, the body cannot properly regulate calcium and phosphorus, resulting in:
- Hypocalcemia (low blood calcium)
- Hyperphosphatemia (high phosphorus)
- Symptoms: muscle cramps, tingling and numbness (especially in hands, feet, and lips), muscle spasms (tetany), fatigue, brain fog, and in severe cases, seizures
The most common cause is surgical removal or damage to the parathyroid glands during thyroid or neck surgery. Other causes include autoimmune hypoparathyroidism, genetic conditions, and radiation.
How Was It Treated Before Yorvipath?
For decades, the only treatment was high-dose calcium supplements and active vitamin D (calcitriol). While this manages symptoms for many, it has significant limitations:
- Does not address the underlying hormone deficiency
- Can cause kidney stones, kidney disease, and calcification of soft tissues over time from excessive calcium/vitamin D
- Requires multiple daily doses and constant monitoring
- Many patients still have poor quality of life despite conventional therapy
How Does Yorvipath Work?
Yorvipath is a long-acting PTH analogue administered once daily as a subcutaneous injection (under the skin). Unlike the older PTH injection Natpara (which had to be given twice daily and had a boxed warning for osteosarcoma), Yorvipath:
- Is designed to mimic the sustained, physiologic release of endogenous PTH
- Raises and stabilizes blood calcium levels throughout the day
- Allows reduction or elimination of high-dose calcium and vitamin D supplements
- Reduces the risk of over-supplementation side effects (kidney stones, nephrocalcinosis)
Clinical Evidence
In Phase 3 clinical trials (PaTH Forward), Yorvipath demonstrated:
- ~79% of patients achieved normal calcium levels without conventional therapy
- Significant reductions in calcium and active vitamin D supplement doses
- Improvements in symptoms and quality of life
- Favorable safety profile without the osteosarcoma signal seen with earlier PTH therapies
Administration
- Route: Subcutaneous injection (small needle, like an insulin pen)
- Frequency: Once daily
- Starting dose: 18 mcg/day, titrated based on calcium levels
- Monitoring: Regular serum calcium, phosphorus, urinary calcium, and kidney function checks, especially during initiation and dose adjustment
Side Effects
- Hypercalcemia (high calcium) — the most important side effect to monitor during dose titration
- Nausea
- Headache
- Dizziness
- Injection site reactions
Yorvipath should not be used in patients at increased risk for osteosarcoma (e.g., prior radiation to the skeleton, bone metastases, Paget's disease of bone, or certain genetic conditions affecting the skeleton).
Who Is a Candidate?
Yorvipath is appropriate for adults with chronic hypoparathyroidism who have inadequate control on conventional therapy or who experience complications from high-dose calcium and vitamin D. It is not first-line for newly diagnosed or mild cases that are well-controlled.
Key Takeaways
- Yorvipath is the first approved once-daily PTH replacement therapy for chronic hypoparathyroidism
- It addresses the underlying hormone deficiency — not just the symptoms
- Can normalize calcium and allow reduction of high-dose calcium/vitamin D supplements
- Regular monitoring of calcium levels is essential, especially at initiation
- Our endocrinologists evaluate, prescribe, and monitor Yorvipath for appropriate patients
Our Team Can Help with Your Medications
All five of our providers prescribe and manage endocrine medications. Book with any member of our team:
Book an Appointment → or call 832-968-7003